|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Effect of vitamin D supple- mentation on blood pressure in blaeks显示文摘 | Forman JP Scott JB Ng K | 2013 | Hypertension2013，61，4： | 1 |
| 2 | Proteomic profiling to i- dentify prognostic biomarkers in heart failure显示文摘 | Scott PA Zeidan B Ng LL | 2012 | In Vi- vo2012，26，6： | 1 |
| 3 | Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex 显示文摘 | Scott AP Laing NG Mastaglia F | 2011 | J Neuroimmunol2011，235，： | 1 |
| 4 | hSIR2 SIRT1 Functions as an NAD-Dependent p53 Deacetylase显示文摘 | Homayoun Vaziri Scott K. Dessain Elinor Ng Eaton Shin-Ichiro Imai Roy A. Frye Tej K. Pandita Leonard Guarente Robert A. Weinberg | 2001 | Cell2001，，： | 1 |
| 5 | Recombination mapping of the susceptibility region for sporadic inclusion body myositis within the major histocompatibility complex显示文摘 | Scott AP Laing NG Mastaglia F | 2011 | J Neuroimmunol2011，235，12： | 1 |
| 6 | Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents显示文摘 | Scott NG Ripperger-Suhler J Rajab MH | 2010 | J Child Adolesc Psychopharmacol2010，20，3： | 1 |
| 7 | Spectroscopic(multi- energy) CT distinguishes iodine and barium contrast material in MICE显示文摘 | Anderson NG Butler AP Scott NJ | 2010 | Eur Radiol2010，20，9： | 1 |
| 8 | Weather changes and pain rheumatology patients 显示文摘 | Jennifer NG David Scott Ashish Taneja | 2004 | APLAR Journal Rheumatology2004，，7： | 1 |
| 9 | The relationship betweenbreastfeeding and weight status in a national sample ofAustralian children and adolescents 显示文摘 | Scott JA Ng SY Cobiac L | 2012 | BMC PublicHealth2012，12，： | 1 |
| 10 | hSIR2 SIRT1 Functions as an NAD-Dependent p53 Deacetylase显示文摘 | Homayoun Vaziri Scott K. Dessain Elinor Ng Eaton Shin-Ichiro Imai Roy A. Frye Tej K. Pandita Leonard Guarente Robert A. Weinberg | 2001 | Cell2001，，2： | 1 |
| 11 | Spectroscopic (multi-energy) CT distinguishes iodine and barium contrast material in MICE 显示文摘 | Anderson NG Butler AP Scott NJA | 2010 | Eur Radiol2010，20，9： | 1 |
| 12 | LAPAROSCOPIC MANAGEMENT OF CALICEAL DIVERTICULAR CALCULI显示文摘 | SCOTT D. MILLER CHRISTOPHER S. NG STEVAN B. STREEM INDERBIR S. GILL | 2002 | The Journal of Urology2002，，3： | 1 |
| 13 | Effect of vitamin D supplementation on blood pressure in blacks 显示文摘 | Forman JP Scott JB Ng K | 2013 | Hypertension2013，61，4： | 1 |
| 14 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge. | Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch | 2016 | World Journal of Gastroenterology2016，22，9： | 1 |
| 15 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 16 | Effect of vitamin D supplementation on blood pressure in blacks显示文摘 | Forman JP Scott JB Ng K | 2013 | Hyper- tension2013，61，4： | 1 |
| 17 | Spectroscopic (multi- energy) CT distinguishes iodine and barium contrast material in MICE显示文摘 | Anderson NG Butler AP Scott NJ | 2010 | Eur Radiol2010，20，9： | 1 |
| 18 | Prostaglandin E2 im- prints a long-lasting effect on dendritic cell progenitors in the bone marrow 显示文摘 | Scott NM Ng RL Gorman S | 2014 | J Leukoc Biol2014，95，： | 1 |
| 19 | Spectroscopic (multi energy) CT distinguishes iodine and arium contrast material in MICE显示文摘 | Anderson NG Butler Ap Scott NJ | | 0，，09： | 1 |
| 20 | Targeted left ventricular endoeardial pacing using a steerable introducing guide catheter and active fixation pacing lead 显示文摘 | Morgan JM Scott PA Turner NG | 2009 | Europace2009，11，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员